By Joe Carlson
Modern Healthcare
Posted: November 4, 2013
In the largest-ever legal settlement for sales of a single drug, Johnson & Johnson has agreed to pay more than $2 billion and plead guilty to a misdemeanor charge of misbranding to end long-running investigations of its sales tactics involving Risperdal.
The New Brunswick, N.J.-based company and subsidiaries Janssen Pharmaceuticals and Scios told investors in August 2011 that they had agreed to settle allegations that J&J promoted its anti-psychotic Risperdal for off-label uses. On Thursday, company officials are scheduled to plead guilty in federal court.
The entire story is here.
